About the Company
We do not have any company description for VIVOS INC at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on VIVOS INC
Vivos Inc. Extended its IsoPet® Precision ... - Markets Insider
About Vivos Inc. (OTCQB: RDGL) Vivos Inc. has developed an Yttrium-90-based injectable Precision Radionuclide Therapy™ medical device to treat tumors in animals (IsoPet ®) and humans (RadioGel ®).
Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024 ...
Vivos Inc. has developed an Yttrium-90-based injectable Precision Radionuclide Therapy™ medical device to treat tumors in animals (IsoPet ®) and humans (RadioGel ®).
Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse ... - Nasdaq
--Vivos Inc., Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the injection of hydrogel into spleens in mice. These tests ...
Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to ...
About Vivos Inc. (OTCQB: RDGL) Vivos Inc. has developed an Yttrium-90-based injectable Precision Radionuclide Therapy™ medical device to treat tumors in animals (IsoPet ®) and humans (RadioGel ®).
Vivos Inc. Submits the Application to the FDA for Authority to Initiate ...
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (RDGL) (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). In closing Dr. Korenko stated ...
Vivos Therapeutics, Inc. to Release First Quarter 2025 ... - Nasdaq
Vivos Therapeutics, Inc. announced it will release its first quarter 2025 financial results on May 15, 2025, after market close, followed by a conference call at 5:00 p.m. ET to discuss the ...
Vivos Therapeutics Delays Q2 2025 10-Q Filing
Vivos Therapeutics ( ($VVOS) ) has released a notification of late filing. Vivos Therapeutics, Inc. has announced a delay in filing its Form 10-Q ...
Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet ...
Vivos Inc. has developed an Yttrium-90 based injectable Precision Radionuclide Therapy brachytherapy device, for the treatment of tumors in animals (IsoPet ®) and in humans (RadioGel ™).
Vivos Inc.'s Says Its Innovative Cancer Treatment Will Offer New ...
Vivos Inc.’s RadioGel®, another PRnT™-based therapy aimed at cancer treatment in humans, is currently developing momentum on the way to FDA approval.
Vivos Inc. Research & Ratings | RDGL | Barron's
Vivos, Inc. is a radiation oncology medical device company. It is engaged in the development of its yttrium-90 based brachytherapy device, RadioGel, for the treatment of non-resectable tumors.
Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024 ...
Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to announce the significant achievements of its IsoPet® Animal Cancer Division, setting new milestones in ...
Similar Companies
Loading the latest forecasts...